An observational study in Metabolic Syndrome (MetS), Hypertension (HTN) and Obesity, sponsored by The Third Xiangya Hospital of Central South University. Completed at 3 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by The Third Xiangya Hospital of Central South University · Observational
This study is designed to understand how bariatric surgery affects patients with metabolic syndrome over both the short and long term. We will track changes in blood pressure and other health indicators for up to 10 years after surgery. The goal is to see whether surgery can provide lasting benefits for controlling blood pressure and improving overall health in patients with metabolic syndrome.
Metabolic syndrome (MetS) is a combination of obesity, high blood pressure, abnormal blood sugar, and lipid disorders. It greatly increases the risk of heart disease, stroke, and type 2 diabetes. In Asian populations, MetS often appears at lower body mass index (BMI) levels than in Western countries, making it a growing public health concern even among individuals without severe obesity.
Bariatric surgery has been proven to help patients lose weight and improve blood sugar, blood pressure, and cholesterol levels. However, most studies have been done in patients with severe obesity. There is limited real-world evidence on how surgery affects patients with MetS at lower BMI levels, especially over the long term. In addition, the short-term biological changes that occur immediately after surgery are not fully understood.
This study is a multicenter prospective cohort including patients who had bariatric surgery in three hospitals in China. Patients are being followed for up to 10 years after surgery.
The primary outcome is improvement or resolution of MetS, defined by standardized criteria including BMI, blood pressure, fasting glucose, and lipid levels. Secondary outcomes include changes in individual risk factors, reduction in medication use, and the proportion of patients free of MetS over time.
By providing both short-term and long-term data, this study will clarify how bariatric surgery affects the full course of MetS. The results will help identify patients who may benefit most, guide treatment recommendations, and support better prevention of cardiovascular and metabolic diseases in Asian populations.
1,963 studies on the registry are indexed under Metabolic Syndrome; 329 are open to participants now.
This study's enrollment of 1,581 is above the median of 200 across 458 observational studies indexed under Metabolic Syndrome.
Browse Metabolic Syndrome studies →The Third Xiangya Hospital of Central South University is the lead sponsor of 95 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of adult patients aged 18 to 65 years who were scheduled to undergo bariatric surgery, including laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), at three participating medical centers in China. Patients were selected based on guideline-based indications for bariatric surgery at the time of recruitment. For the primary analysis, only patients with hypertension were included, defined as meeting at least one of the following criteria: (1) systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg; (2) self-reported or physician-diagnosed hypertension; or (3) current use of antihypertensive medications. Patients with coexisting cardiac insufficiency, renal dysfunction, contraindications to surgery or anesthesia, or who declined participation were excluded. Additional exclusions during the data analysis phase included patients who experienced severe postoperative adverse events within 7 days, had fewer tha
Exclusion Criteria:
Weight
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
Body Mass Index
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
Systolic blood pressure
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
Diastolic blood pressure
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
Status of hypertension
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
Fasting blood glucose
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
Total cholesterol
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
Triglycerides
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
Glycated hemoglobin
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
Low-density lipoprotein (LDL)
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
High-density lipoprotein (HDL)
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
excess weight loss (EWL%)
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
Fasting insulin
Time frame: postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Third Xiangya Hospital of Central South University